Table 2.
Supplementation effect on patients’ concomitant conventional IBS treatment at T0 and T1 (n = 146).
| Concomitant IBS Treatment | Number of Medications or Use | T0 | T1 | Percent Decrease in Patients on Concomitant Treatment |
|---|---|---|---|---|
| n (%) | n (%) | |||
| Antispasmodic medication | 64.0 | |||
| 0 | 96 (65.8) | 128 (87.7) | ||
| 1 | 43 (29.4) | 14 (9.6) | ||
| 2 | 7 (4.8) | 3 (2.0) | ||
| 3 | 1 (0.7) | |||
| Antidiarrhoeic medication | 64.6 | |||
| 0 | 132 (90.4) | 141 (96.6) | ||
| 1 | 13 (8.9) | 3 (2.0) | ||
| 2 | 1 (0.7) | 2 (1.4) | ||
| Laxative medication | 13.3 | |||
| 0 | 123 (84.2) | 126 (86.3) | ||
| 1 | 19 (13.1) | 19 (13.0) | ||
| 2 | 4 (2.7) | 1 (0.7) | ||
| Antidepressants benzodiazepines | 8.9 | |||
| No | 97 (66.4) | 100 (69.4) | ||
| Yes | 49 (33.6) | 44 (30.6) | ||
| Probiotics | 38.0 | |||
| No | 101 (69.7) | 117 (81.2) | ||
| Yes | 44 (30.3) | 27 (18.8) | ||
| Food restriction | 28.5 | |||
| No | 88 (61.1) | 104 (72.2) | ||
| Yes | 56 (38.9) | 40 (27.8) |
T0: baseline visit, T1: after the 2-month BBR–CUR supplementation follow-up visit.